-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on May 31 A few days ago, Renfu Pharmaceutical's Class 1 new drug, propofol disodium for injection, was approved for marketing.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
Since 2011, domestic Class 1 new drugs have been approved as TOP10 companies
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
60 domestically produced Class 1 new drugs involve more than 40 companies (in terms of the group), and 10 companies including Hengrui, Hausen, BeiGene, Simcere, Beida, Gery, and Hutchison Whampoa have been approved for 2 varieties And above.
Domestic Class 1 new drugs with sales exceeding 1 billion yuan in 2020
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
The total sales of 11 varieties in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 will exceed 1 billion yuan.
Hengrui, Zhengda Tianqing The performance is eye-catching.
Hengrui, Zhengda Tianqing The performance is eye-catching.
A few days ago (April 30), the National Medical Insurance Bureau announced that as of April 15th, 19 newly negotiated drugs with clinical priority and low substitutability entered 3324 designated medical institutions, including 1,417 medical institutions and retail pharmacies.
1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
"Innovative Drug One Brother" 6 new category 1 new drugs are dazzling, with 3 annual sales exceeding 1 billion
Hengrui Medicine has been approved for the listing of 6 Class 1 new drugs, and the total domestic sales in 2020 will exceed 8 billion yuan.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
PD-1 carrelizumab has not been on the market for a long time, but it has quickly become Hengrui's blockbuster product.
Currently, the terminal covers 29 provinces and has as many as 634 institutions (387 medical institutions and 247 retail pharmacies).
The product's domestic sales in 2020 will be close to 4 billion yuan, and 5 indications have been approved, 4 indications have been negotiated and included in the national medical insurance in 2020, and more than 10 combination medications/new indications are in phase III In clinical practice, relying on the domestic and foreign synchronous R&D strategies of "major diseases" and "combination" of medical insurance, "major diseases" and "combination", and a strong marketing team, carrelizumab can be expected in the future; apatinib mesylate sales in 2020 Over 2 billion yuan, currently 2 indications have been approved for marketing, and more than 5 combination drug regimens/new indications are undergoing phase III clinical trials.
Currently, the terminal covers 29 provinces and has as many as 634 institutions (387 medical institutions and 247 retail pharmacies).
The product's domestic sales in 2020 will be close to 4 billion yuan, and 5 indications have been approved, 4 indications have been negotiated and included in the national medical insurance in 2020, and more than 10 combination medications/new indications are in phase III In clinical practice, relying on the domestic and foreign synchronous R&D strategies of "major diseases" and "combination" of medical insurance, "major diseases" and "combination", and a strong marketing team, carrelizumab can be expected in the future; apatinib mesylate sales in 2020 Over 2 billion yuan, currently 2 indications have been approved for marketing, and more than 5 combination drug regimens/new indications are undergoing phase III clinical trials.
Fluzoparib, approved in 2020, is the first domestically produced PARP inhibitor.
The new indication for maintenance treatment of ovarian cancer has been submitted for marketing.
In addition, there are indications for advanced ovarian cancer, breast cancer, prostate cancer, and metastatic pancreatic cancer.
Phase III clinical trials; remazolam tosylate is a new type of short-acting GABAa receptor agonist.
The two major indications for gastroscopy and colonoscopy have been approved.
General anesthesia, bronchoscopy and sedation have been approved.
Symptoms have submitted a listing application.
The new indication for maintenance treatment of ovarian cancer has been submitted for marketing.
In addition, there are indications for advanced ovarian cancer, breast cancer, prostate cancer, and metastatic pancreatic cancer.
Phase III clinical trials; remazolam tosylate is a new type of short-acting GABAa receptor agonist.
The two major indications for gastroscopy and colonoscopy have been approved.
General anesthesia, bronchoscopy and sedation have been approved.
Symptoms have submitted a listing application.
At present, Hengrui Medicine has a number of Class 1 new drugs under review and approval, including SHR6390 (CDK4/6 selective inhibitor), Hetropopaethanolamine (TPOR agonist), Retagliptin phosphate (DPP) -4 inhibitor), proline Henggliflozin (SGLT2 inhibitor), linpril (PI3Kδ selective inhibitor).
Hausen Pharmaceuticals was approved for 4 Class 1 new drugs, setting a number of domestic firsts
Hausen has 4 Class 1 new drugs approved for marketing.
Ametinib mesylate tablets, flumatinib mesylate tablets, and polyethylene glycol loxenatide injection will be included in the national medical insurance through negotiations in 2020.
Ametinib mesylate terminals cover 26 provinces with 411 institutions (150 medical institutions and 261 retail pharmacies), and flumatinib mesylate terminals cover 24 provinces with 297 institutions (medical institutions) 85 stores and 121 retail pharmacies).
Ametinib mesylate tablets, flumatinib mesylate tablets, and polyethylene glycol loxenatide injection will be included in the national medical insurance through negotiations in 2020.
Ametinib mesylate terminals cover 26 provinces with 411 institutions (150 medical institutions and 261 retail pharmacies), and flumatinib mesylate terminals cover 24 provinces with 297 institutions (medical institutions) 85 stores and 121 retail pharmacies).
Flumatinib mesylate is the first domestically produced new second-generation BCR-ABL tyrosine kinase inhibitor.
In 2020, its domestic sales will exceed 100 million yuan, a year-on-year increase of more than 1,000%.
In the research and development of this target, Hausen Pharmaceuticals has gone from the first generic drug imatinib to the innovative drug flumatinib, and has taken the road of upgrading from imitation to innovation.
In 2020, its domestic sales will exceed 100 million yuan, a year-on-year increase of more than 1,000%.
In the research and development of this target, Hausen Pharmaceuticals has gone from the first generic drug imatinib to the innovative drug flumatinib, and has taken the road of upgrading from imitation to innovation.
Polyethylene glycol loxenatide is the first domestically produced long-acting GLP-1 receptor agonist and the world's first PEGylated long-acting GLP-1 receptor agonist.
In addition, it is Hausen Pharmaceuticals in the field of hypoglycemic drugs.
China’s first innovative drug, domestic sales in 2020 will exceed 50 million yuan, a year-on-year increase of more than 300%.
In addition, it is Hausen Pharmaceuticals in the field of hypoglycemic drugs.
China’s first innovative drug, domestic sales in 2020 will exceed 50 million yuan, a year-on-year increase of more than 300%.
Ametinib mesylate is the first domestically produced third-generation EGFR-TKI inhibitor, directly against osimertinib (global sales of more than 4 billion U.
S.
dollars in 2020).
The product was approved for marketing in March 2020 and will be included in the national medical insurance through negotiations at the end of the year.
S.
dollars in 2020).
The product was approved for marketing in March 2020 and will be included in the national medical insurance through negotiations at the end of the year.
At present, Haosen Pharmaceuticals still has one new class 1 drug submitted for marketing.
Emifenamine Tenofovir Tablets are nucleoside reverse transcriptase inhibitors independently developed by the company, which can improve curative effect and reduce toxic side effects.
The new tenofovir prodrug; Inebilizumab injection, which was introduced under technical license, applied for import, and it was the first anti-CD19 monoclonal antibody to be produced in China.
Emifenamine Tenofovir Tablets are nucleoside reverse transcriptase inhibitors independently developed by the company, which can improve curative effect and reduce toxic side effects.
The new tenofovir prodrug; Inebilizumab injection, which was introduced under technical license, applied for import, and it was the first anti-CD19 monoclonal antibody to be produced in China.
Three new class 1 drugs have been approved one after another, BeiGene enters the harvest period
As the company with the highest R&D investment among listed pharmaceutical companies , BeiGene’s R&D achievements have been realized one after another.
During the period 2020-2021, the company has successively approved 3 new class 1 drugs.
Tilelizumab and Zebutinib will be included in the national medical insurance through negotiations in 2020.
Currently, tislelizumab covers 24 terminals.
Provinces, with 100 institutions (100 medical institutions, 0 retail pharmacies).
During the period 2020-2021, the company has successively approved 3 new class 1 drugs.
Tilelizumab and Zebutinib will be included in the national medical insurance through negotiations in 2020.
Currently, tislelizumab covers 24 terminals.
Provinces, with 100 institutions (100 medical institutions, 0 retail pharmacies).
Tilelizumab is the fourth domestically produced PD-1 approved for listing in China, and it is the company's first category 1 new drug approved for listing.
In 2020, domestic sales will reach 990 million yuan, and it is likely to exceed 1 billion yuan next year.
At present, the product has been approved for 3 indications, and 3 new indications/combinations have been submitted for marketing applications.
In 2020, domestic sales will reach 990 million yuan, and it is likely to exceed 1 billion yuan next year.
At present, the product has been approved for 3 indications, and 3 new indications/combinations have been submitted for marketing applications.
Zebutinib is a BTK inhibitor independently developed by BeiGene and was approved by the FDA in November 2019, bringing a "zero breakthrough" for Chinese original new drugs to go overseas; in June 2020, it was approved by the National Food and Drug Administration for marketing , Becoming the first domestically approved BTK inhibitor with domestic sales exceeding 200 million yuan in 2020.
At present, the product has been approved for 2 indications, and the third indication has been reported for production.
At present, the product has been approved for 2 indications, and the third indication has been reported for production.
Among the new drugs being developed, the imported licensed drugs carfilzomib, belintouximab, stuximab, and dituximab have been applied for listing and will continue to enter the Chinese market in the future.
Source: Mi Nei Net Database
Note: The statistics are as of May 26, if there are any omissions, please correct me!
Medical Network News on May 31 A few days ago, Renfu Pharmaceutical's Class 1 new drug, propofol disodium for injection, was approved for marketing.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
Since 2011, domestic Class 1 new drugs have been approved as TOP10 companies
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
60 domestically produced Class 1 new drugs involve more than 40 companies (in terms of the group), and 10 companies including Hengrui, Hausen, BeiGene, Simcere, Beida, Gery, and Hutchison Whampoa have been approved for 2 varieties And above.
Domestic Class 1 new drugs with sales exceeding 1 billion yuan in 2020
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
The total sales of 11 varieties in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 will exceed 1 billion yuan.
Hengrui, Zhengda Tianqing The performance is eye-catching.
Hengrui, Zhengda Tianqing The performance is eye-catching.
A few days ago (April 30), the National Medical Insurance Bureau announced that as of April 15th, 19 newly negotiated drugs with clinical priority and low substitutability entered 3324 designated medical institutions, including 1,417 medical institutions and retail pharmacies.
1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
"Innovative Drug One Brother" 6 new category 1 new drugs are dazzling, with 3 annual sales exceeding 1 billion
Hengrui Medicine has been approved for the listing of 6 Class 1 new drugs, and the total domestic sales in 2020 will exceed 8 billion yuan.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
PD-1，，29，634（387，247）。202040，5，42020，10/III，、“”“”、，；202020，2，5/III。
2020PARP，，、、、III；GABAa，、2，、。
1，SHR6390（CDK4/6）、（TPOR）、（DPP-4）、（SGLT2）、（PI3Kδ）。
41，
41，、、2020，26，411（150，261），24，297（85，121）。
BCR-ABL，20201，1000%。，，。
GLP-1，PEGGLP-1，，20205000，300%。
EGFR-TKI，“”（202040）。20203，。
11，，；，Inebilizumab，CD19。
31，
，。2020-2021，31，、2020，24，100（100，0）。
4PD-1，1，20209.
9，10。3，3/。
9，10。3，3/。
BTK，201911FDA，“”；20206，BTK，20202。2，3。
，、、、，。
：
：526，，！
Medical Network News on May 31 A few days ago, Renfu Pharmaceutical's Class 1 new drug, propofol disodium for injection, was approved for marketing.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
According to Meinenet data, in the past 10 years (2011-present), about 60 domestically produced Class 1 new drugs (including 1.
3, 1.
5 and 1.
6) have been approved for listing, 11 of which will be listed in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020.
The total terminal sales exceeded 1 billion yuan.
The number of new drugs approved by 10 companies reached 2 or more.
Hengrui led with 6 new drugs, Hausen followed closely with 4 new drugs, and BeiGene was approved for 3 new drugs.
Since 2011, domestic Class 1 new drugs have been approved as TOP10 companies
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
60 domestically produced Class 1 new drugs involve more than 40 companies (in terms of the group), and 10 companies including Hengrui, Hausen, BeiGene, Simcere, Beida, Gery, and Hutchison Whampoa have been approved for 2 varieties And above.
Domestic Class 1 new drugs with sales exceeding 1 billion yuan in 2020
Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
The total sales of 11 varieties in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 will exceed 1 billion yuan.
Hengrui, Zhengda Tianqing The performance is eye-catching.
Hospital hospital hospital pharmacy pharmacy pharmacyHengrui, Zhengda Tianqing The performance is eye-catching.
A few days ago (April 30), the National Medical Insurance Bureau announced that as of April 15th, 19 newly negotiated drugs with clinical priority and low substitutability entered 3324 designated medical institutions, including 1,417 medical institutions and retail pharmacies.
1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
Drugs Drugs Drugs medicine medicine medicine1907 companies, including Hengrui's carrelizumab, Hausen's ametinib mesylate and flumatinib mesylate, BeiGene's tislelizumab, etc.
"Innovative Drug One Brother" 6 new category 1 new drugs are dazzling, with 3 annual sales exceeding 1 billion
"Innovative Drug One Brother" 6 new category 1 new drugs are dazzling, with 3 annual sales exceeding 1 billion Hengrui Medicine has been approved for the listing of 6 Class 1 new drugs, and the total domestic sales in 2020 will exceed 8 billion yuan.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
Among them, carrelizumab, pyrrotinib, and apatinib are more than 1 billion varieties.
All have been included in the national medical insurance.
Irecoxib began to increase its volume after entering the national medical insurance in 2017.
In 2020, its domestic sales will exceed 800 million yuan, a year-on-year increase of 20%, and it may exceed the 1 billion mark next year.
PD-1 carrelizumab has not been on the market for a long time, but it has quickly become Hengrui's blockbuster product.
Currently, the terminal covers 29 provinces and has as many as 634 institutions (387 medical institutions and 247 retail pharmacies).
The product's domestic sales in 2020 will be close to 4 billion yuan, and 5 indications have been approved, 4 indications have been negotiated and included in the national medical insurance in 2020, and more than 10 combination medications/new indications are in phase III In clinical practice, relying on the domestic and foreign synchronous R&D strategies of "major diseases" and "combination" of medical insurance, "major diseases" and "combination", and a strong marketing team, carrelizumab can be expected in the future; apatinib mesylate sales in 2020 Over 2 billion yuan, currently 2 indications have been approved for marketing, and more than 5 combination drug regimens/new indications are undergoing phase III clinical trials.
Currently, the terminal covers 29 provinces and has as many as 634 institutions (387 medical institutions and 247 retail pharmacies).
The product's domestic sales in 2020 will be close to 4 billion yuan, and 5 indications have been approved, 4 indications have been negotiated and included in the national medical insurance in 2020, and more than 10 combination medications/new indications are in phase III In clinical practice, relying on the domestic and foreign synchronous R&D strategies of "major diseases" and "combination" of medical insurance, "major diseases" and "combination", and a strong marketing team, carrelizumab can be expected in the future; apatinib mesylate sales in 2020 Over 2 billion yuan, currently 2 indications have been approved for marketing, and more than 5 combination drug regimens/new indications are undergoing phase III clinical trials.
Fluzoparib, approved in 2020, is the first domestically produced PARP inhibitor.
The new indication for maintenance treatment of ovarian cancer has been submitted for marketing.
In addition, there are indications for advanced ovarian cancer, breast cancer, prostate cancer, and metastatic pancreatic cancer.
Phase III clinical trials; remazolam tosylate is a new type of short-acting GABAa receptor agonist.
The two major indications for gastroscopy and colonoscopy have been approved.
General anesthesia, bronchoscopy and sedation have been approved.
Symptoms have submitted a listing application.
The new indication for maintenance treatment of ovarian cancer has been submitted for marketing.
In addition, there are indications for advanced ovarian cancer, breast cancer, prostate cancer, and metastatic pancreatic cancer.
Phase III clinical trials; remazolam tosylate is a new type of short-acting GABAa receptor agonist.
The two major indications for gastroscopy and colonoscopy have been approved.
General anesthesia, bronchoscopy and sedation have been approved.
Symptoms have submitted a listing application.
At present, Hengrui Medicine has a number of Class 1 new drugs under review and approval, including SHR6390 (CDK4/6 selective inhibitor), Hetropopaethanolamine (TPOR agonist), Retagliptin phosphate (DPP) -4 inhibitor), proline Henggliflozin (SGLT2 inhibitor), linpril (PI3Kδ selective inhibitor).
Hausen Pharmaceuticals was approved for 4 Class 1 new drugs, setting a number of domestic firsts
Hausen Pharmaceuticals was approved for 4 Class 1 new drugs, setting a number of domestic firsts Hausen has 4 Class 1 new drugs approved for marketing.
Ametinib mesylate tablets, flumatinib mesylate tablets, and polyethylene glycol loxenatide injection will be included in the national medical insurance through negotiations in 2020.
Ametinib mesylate terminals cover 26 provinces with 411 institutions (150 medical institutions and 261 retail pharmacies), and flumatinib mesylate terminals cover 24 provinces with 297 institutions (medical institutions) 85 stores and 121 retail pharmacies).
Ametinib mesylate tablets, flumatinib mesylate tablets, and polyethylene glycol loxenatide injection will be included in the national medical insurance through negotiations in 2020.
Ametinib mesylate terminals cover 26 provinces with 411 institutions (150 medical institutions and 261 retail pharmacies), and flumatinib mesylate terminals cover 24 provinces with 297 institutions (medical institutions) 85 stores and 121 retail pharmacies).
Flumatinib mesylate is the first domestically produced new second-generation BCR-ABL tyrosine kinase inhibitor.
In 2020, its domestic sales will exceed 100 million yuan, a year-on-year increase of more than 1,000%.
In the research and development of this target, Hausen Pharmaceuticals has gone from the first generic drug imatinib to the innovative drug flumatinib, and has taken the road of upgrading from imitation to innovation.
In 2020, its domestic sales will exceed 100 million yuan, a year-on-year increase of more than 1,000%.
In the research and development of this target, Hausen Pharmaceuticals has gone from the first generic drug imatinib to the innovative drug flumatinib, and has taken the road of upgrading from imitation to innovation.
Polyethylene glycol loxenatide is the first domestically produced long-acting GLP-1 receptor agonist and the world's first PEGylated long-acting GLP-1 receptor agonist.
In addition, it is Hausen Pharmaceuticals in the field of hypoglycemic drugs.
China’s first innovative drug, domestic sales in 2020 will exceed 50 million yuan, a year-on-year increase of more than 300%.
In addition, it is Hausen Pharmaceuticals in the field of hypoglycemic drugs.
China’s first innovative drug, domestic sales in 2020 will exceed 50 million yuan, a year-on-year increase of more than 300%.
Ametinib mesylate is the first domestically produced third-generation EGFR-TKI inhibitor, directly against osimertinib (global sales of more than 4 billion U.
S.
dollars in 2020).
The product was approved for marketing in March 2020 and will be included in the national medical insurance through negotiations at the end of the year.
S.
dollars in 2020).
The product was approved for marketing in March 2020 and will be included in the national medical insurance through negotiations at the end of the year.
At present, Haosen Pharmaceuticals still has one new class 1 drug submitted for marketing.
Emifenamine Tenofovir Tablets are nucleoside reverse transcriptase inhibitors independently developed by the company, which can improve curative effect and reduce toxic side effects.
The new tenofovir prodrug; Inebilizumab injection, which was introduced under technical license, applied for import, and it was the first anti-CD19 monoclonal antibody to be produced in China.
Emifenamine Tenofovir Tablets are nucleoside reverse transcriptase inhibitors independently developed by the company, which can improve curative effect and reduce toxic side effects.
The new tenofovir prodrug; Inebilizumab injection, which was introduced under technical license, applied for import, and it was the first anti-CD19 monoclonal antibody to be produced in China.
Three new class 1 drugs have been approved one after another, BeiGene enters the harvest period
Three new class 1 drugs have been approved one after another, BeiGene enters the harvest period As the company with the highest R&D investment among listed pharmaceutical companies , BeiGene’s R&D achievements have been realized one after another.
During the period 2020-2021, the company has successively approved 3 new class 1 drugs.
Tilelizumab and Zebutinib will be included in the national medical insurance through negotiations in 2020.
Currently, tislelizumab covers 24 terminals.
Provinces, with 100 institutions (100 medical institutions, 0 retail pharmacies).
Enterprise business enterpriseDuring the period 2020-2021, the company has successively approved 3 new class 1 drugs.
Tilelizumab and Zebutinib will be included in the national medical insurance through negotiations in 2020.
Currently, tislelizumab covers 24 terminals.
Provinces, with 100 institutions (100 medical institutions, 0 retail pharmacies).
Tilelizumab is the fourth domestically produced PD-1 approved for listing in China, and it is the company's first category 1 new drug approved for listing.
In 2020, domestic sales will reach 990 million yuan, and it is likely to exceed 1 billion yuan next year.
At present, the product has been approved for 3 indications, and 3 new indications/combinations have been submitted for marketing applications.
In 2020, domestic sales will reach 990 million yuan, and it is likely to exceed 1 billion yuan next year.
At present, the product has been approved for 3 indications, and 3 new indications/combinations have been submitted for marketing applications.
Zebutinib is a BTK inhibitor independently developed by BeiGene and was approved by the FDA in November 2019, bringing a "zero breakthrough" for Chinese original new drugs to go overseas; in June 2020, it was approved by the National Food and Drug Administration for marketing , Becoming the first domestically approved BTK inhibitor with domestic sales exceeding 200 million yuan in 2020.
At present, the product has been approved for 2 indications, and the third indication has been reported for production.
At present, the product has been approved for 2 indications, and the third indication has been reported for production.
Among the new drugs being developed, the imported licensed drugs carfilzomib, belintouximab, stuximab, and dituximab have been applied for listing and will continue to enter the Chinese market in the future.
Source: Mi Nei Net Database
Note: The statistics are as of May 26, if there are any omissions, please correct me!
